title: Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.
abstract: Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.
authors.affiliation: Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain. alberola_vicara@gva.es
authors.forename: Vicente
authors.initials: V
authors.lastname: Alberola Candel
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato Mena
authors.forename: Eduardo
authors.initials: E
authors.lastname: Díaz-Rubio García
authors.forename: Pere
authors.initials: P
authors.lastname: Gascón Vilaplana
authors.forename: Manuel
authors.initials: M
authors.lastname: González Barón
authors.forename: Miguel
authors.initials: M
authors.lastname: Martín Jiménez
authors.forename: Emilio
authors.initials: E
authors.lastname: Alba Conejo
authors.forename: Javier
authors.initials: J
authors.lastname: Cassinello Espinosa
authors.forename: Ramon
authors.initials: R
authors.lastname: Colomer
authors.forename: Juan Jesús
authors.initials: JJ
authors.lastname: Cruz Hernández
authors.forename: Agustí
authors.initials: A
authors.lastname: Barnadas i Molins
authors.forename: Carlos
authors.initials: C
authors.lastname: Camps Herrero
authors.forename: Ana Ma
authors.initials: AM
authors.lastname: Casas Fernández de Tejerina
authors.forename: Joan
authors.initials: J
authors.lastname: Carulla Torrent
authors.forename: Manuel
authors.initials: M
authors.lastname: Constenla Figueiras
authors.forename: Joaquin
authors.initials: J
authors.lastname: Gavilá Gregori
authors.forename: Ma Dolores
authors.initials: MD
authors.lastname: Isla Casado
authors.forename: Bartomeu
authors.initials: B
authors.lastname: Massuti Sureda
authors.forename: Mariano
authors.initials: M
authors.lastname: Provencio Pulla
authors.forename: César Augusto
authors.initials: CA
authors.lastname: Rodríguez Sánchez
authors.forename: Jaime
authors.initials: J
authors.lastname: Sanz Ortiz
mesh_terms: D000740:Anemia / Q000150:complications* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001803:Blood Transfusion; D002908:Chronic Disease / Q000628:therapy; D002986:Clinical Trials as Topic; D004912:Erythrocytes / Q000378:metabolism; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D008495:Medical Oncology / Q000379:methods*; D009369:Neoplasms / Q000150:complications*; D017410:Practice Guidelines as Topic; D013030:Spain
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D007501:Iron